The Therapeutic Goods
Administration and Aimedics have
recalled all units of the HypoMon
sleep-time hypoglycaemic monitor.
HypoMon is used by people with
type 1 diabetes aged 10-25 years to
monitor blood glucose while they
sleep, but unfortunately it has been
identified that HypoMon is not
performing as well as expected.
“The rate of detection of sleeptime
hypoglcaemic episodes is
lower than the rate specified,”
according to a TGA update.
The manufacturer Aimedics is
providing a full refund.
A number of HypoMons have
been funded by the Danii Meads-
Barlow Foundation, which is now
subsidising CGM Dexom G4 devices.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.